HANALL BIOPHARMA CO LTD

Hanall Biopharma slides as investors doubt its research‑driven pipeline, questioning whether its biotech breakthroughs can translate into revenue.

Hanall Biopharma shares fell 2.66% to KRW 40,200, amid a 13.5% monthly slump. Explore the company’s 52+ drug pipeline, market context and future prospects.

Check Hanall Biopharma’s latest trade trends, market cap, and R&D pipeline—why its shares slipped yet still hold steady in Korea’s pharma scene.